Drug intelligence / Profile preview

MG01 + T521

Development stage: Unknown
Lead developer: Inmunotek
Modality: Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

MG01 + T521 is a subcutaneous immunotherapy (SCIT) combination used for treating allergies against grass and olive pollen. It consists of two components: MG01, which is derived from a mixture of grasses (Phleum pratense, Holcus lanatus, Poa pratensis, Festuca pratensis, Lolium perenne, and Dactylis glomerata), and T521, which is derived from Olea europaea (olive). Both components are purified allergen extracts that have been polymerized with glutaraldehyde.

Beyond the preview

Go deeper on MG01 + T521.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MG01 + T521.

Explore the full profile